AU6144494A - Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases - Google Patents

Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases

Info

Publication number
AU6144494A
AU6144494A AU61444/94A AU6144494A AU6144494A AU 6144494 A AU6144494 A AU 6144494A AU 61444/94 A AU61444/94 A AU 61444/94A AU 6144494 A AU6144494 A AU 6144494A AU 6144494 A AU6144494 A AU 6144494A
Authority
AU
Australia
Prior art keywords
eye diseases
recombinant adenoviruses
gene therapy
treating eye
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU61444/94A
Other versions
AU693782B2 (en
Inventor
Pascale Briand
Michel Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Rhone Poulenc Rorer SA
Publication of AU6144494A publication Critical patent/AU6144494A/en
Application granted granted Critical
Publication of AU693782B2 publication Critical patent/AU693782B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of defective recombinant adenoviruses containing an inserted gene for preparing a pharmaceutical useful for treating eye diseases is disclosed.
AU61444/94A 1993-03-03 1994-02-28 Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases Ceased AU693782B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9302438 1993-03-03
FR9302438A FR2702152B1 (en) 1993-03-03 1993-03-03 Recombinant viruses and their use in gene therapy.
PCT/FR1994/000220 WO1994020146A1 (en) 1993-03-03 1994-02-28 Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases

Publications (2)

Publication Number Publication Date
AU6144494A true AU6144494A (en) 1994-09-26
AU693782B2 AU693782B2 (en) 1998-07-09

Family

ID=9444602

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61444/94A Ceased AU693782B2 (en) 1993-03-03 1994-02-28 Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases

Country Status (15)

Country Link
EP (1) EP0687184B1 (en)
JP (1) JP3835809B2 (en)
AT (1) ATE220923T1 (en)
AU (1) AU693782B2 (en)
CA (1) CA2154355A1 (en)
DE (1) DE69431046T2 (en)
DK (1) DK0687184T3 (en)
ES (1) ES2181710T3 (en)
FR (1) FR2702152B1 (en)
HU (1) HU218900B (en)
NO (1) NO319571B1 (en)
NZ (1) NZ262135A (en)
PT (1) PT687184E (en)
WO (1) WO1994020146A1 (en)
ZA (1) ZA941426B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US7256181B2 (en) 1997-08-29 2007-08-14 Biogen Idec Ma Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US7465442B2 (en) 2003-11-24 2008-12-16 Canji, Inc. Reduction of dermal scarring

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2726575B1 (en) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY
FR2717823B1 (en) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2717824B1 (en) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2718150B1 (en) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
FR2803207B1 (en) * 1999-12-30 2004-04-30 Aventis Pharma Sa USE OF A VECTOR COMPRISING A NUCLEIC ACID ENCODING AN ANTI-ANGIOGENIC FACTOR FOR THE TREATMENT OF CORNEAL NEOVASCULARIZATIONS
ATE303820T1 (en) * 1999-12-30 2005-09-15 Aventis Pharma Sa USE OF A VECTOR ENCODING AN ANTI-ANGIogenic FACTOR FOR THE TREATMENT OF CORNEA VASCULARIZATION
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
WO2006031689A2 (en) 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
PT2601214T (en) 2010-08-06 2017-12-20 Genzyme Corp Vegf antagonist compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336678C (en) * 1988-09-13 1995-08-15 David L. Berliner Prophylaxis and treatment of nervous system diseases with melanin
JPH06506599A (en) * 1991-04-05 1994-07-28 エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー Inhibition of retroviruses by antisense nucleic acids complementary to packaging sequences

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256181B2 (en) 1997-08-29 2007-08-14 Biogen Idec Ma Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US7465442B2 (en) 2003-11-24 2008-12-16 Canji, Inc. Reduction of dermal scarring
US8329671B2 (en) 2003-11-24 2012-12-11 Canji, Inc. Reduction of dermal scarring

Also Published As

Publication number Publication date
AU693782B2 (en) 1998-07-09
JPH08509208A (en) 1996-10-01
ES2181710T3 (en) 2003-03-01
DE69431046D1 (en) 2002-08-29
ZA941426B (en) 1994-10-04
NO953329L (en) 1995-08-24
ATE220923T1 (en) 2002-08-15
EP0687184B1 (en) 2002-07-24
FR2702152B1 (en) 1995-05-24
NZ262135A (en) 2000-12-22
EP0687184A1 (en) 1995-12-20
FR2702152A1 (en) 1994-09-09
HU9502573D0 (en) 1995-10-30
HU218900B (en) 2000-12-28
NO953329D0 (en) 1995-08-24
NO319571B1 (en) 2005-08-29
JP3835809B2 (en) 2006-10-18
WO1994020146A1 (en) 1994-09-15
CA2154355A1 (en) 1994-09-15
DE69431046T2 (en) 2003-02-13
PT687184E (en) 2002-12-31
HUT73215A (en) 1996-06-28
DK0687184T3 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
AU6144494A (en) Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
AU9028491A (en) Iontophoretic drug delivery electrode and method of hydrating the same
AU6787894A (en) Adenoviral vectors of animal origin and use in gene therapy
EP0859627A4 (en) Mimicking peptides in cancer therapy
EP0690673A4 (en) Systemic gene treatment of connective tissue diseases
WO1994029469A3 (en) Plasmids suitable for gene therapy
AU4253189A (en) Apparatus for the surgical treatment of a point situated in an eye
AU1000488A (en) A light ray radiation device for use in medical treatment of the nose and throat passages
AU2816589A (en) Self-regulated therapeutic agent delivery system and method
AU7678096A (en) Therapeutic medical garments for scars and process
IL117115A0 (en) Process for preparing recombinant adenovirus genomes
AU7272196A (en) Use of hyaluronan in gene therapy
AU5960394A (en) Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
AU6428890A (en) Therapeutic peptides and proteins
EP0679717A3 (en) Soluble interferon -receptor, its preparation and use.
AU5743194A (en) Treatment of dermatological malignancies with biologically active peptides
AU3066789A (en) Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases
AU1095595A (en) Gene therapy vector for the treatment of low or defective red blood cell production
AU6251594A (en) Treatment of cancerous growths with biologically active peptides and protease inhibitors
AU7066794A (en) Hyaluronic acid fragments and their therapeutic use
AU3053595A (en) Therapeutic treatment and preparations
AU7075594A (en) Pack for use in, and method of hormonal replacement therapy
AU5903690A (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e) azepine-6, 11-dione and derivatives as drugs for use in the treatment of urinary incontinence
AU653161C (en) Gene protein products and methods of cell therapy
AU7885998A (en) Use of cis- or transurocamic acid for the treatment of photodermatoses and immunogenic skin diseases